Crossmark

High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial

Crossref DOI link: https://doi.org/10.1016/j.ahj.2018.05.007

Published Print: 2018-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Vardeny, Orly

Udell, Jacob A.

Joseph, Jacob

Farkouh, Michael E.

Hernandez, Adrian F.

McGeer, Alison J.

Talbot, H. Keipp

Bhatt, Deepak L.

Cannon, Christopher P.

Goodman, Shaun G.

Anand, Inder

DeMets, David L.

Temte, Jon

Wittes, Janet

Nichol, Kristin

Yancy, Clyde W.

Gaziano, J. Michael

Cooper, Lawton S.

Kim, KyungMann

Solomon, Scott D.
Funding

Funding for this research was provided by:

NHLBI (U01 HL130163, U01 HL130204)

Sanofi Pasteur

Heart and Stroke Foundation of Canada (ERLI024)

Mount Sinai Hospital/University Health Network AMO Innovation Fund (21502002)
License Information

Text and Data Mining valid from 2018-08-01
More Information

This article is maintained by: Elsevier

Article Title: High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial

Journal Title: American Heart Journal

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ahj.2018.05.007

Content Type: article

Copyright: Published by Elsevier Inc.